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Abstract
Background: Despite the extensive research approaches applied to characterise malignant melanoma, no specific molecular
markers are available that are clearly related to the progression of this disease. In this study, our aims were to define a gene
expression signature associated with the clinical outcome of melanoma patients and to provide an integrative
interpretation of the gene expression -, copy number alterations -, and promoter methylation patterns that contribute to
clinically relevant molecular functional alterations.
Methods: Gene expression profiles were determined using the Affymetrix U133 Plus2.0 array. The NimbleGen Human CGH
Whole-Genome Tiling array was used to define CNAs, and the Illumina GoldenGate Methylation platform was applied to
characterise the methylation patterns of overlapping genes.
Results: We identified two subclasses of primary melanoma: one representing patients with better prognoses and the other
being characteristic of patients with unfavourable outcomes. We assigned 1,080 genes as being significantly correlated with
ulceration, 987 genes were downregulated and significantly enriched in the p53, Nf-kappaB, and WNT/beta-catenin
pathways. Through integrated genome analysis, we defined 150 downregulated genes whose expression correlated with
copy number losses in ulcerated samples. These genes were significantly enriched on chromosome 6q and 10q, which
contained a total of 36 genes. Ten of these genes were downregulated and involved in cell-cell and cell-matrix adhesion or
apoptosis. The expression and methylation patterns of additional genes exhibited an inverse correlation, suggesting that
transcriptional silencing of these genes is driven by epigenetic events.
Conclusion: Using an integrative genomic approach, we were able to identify functionally relevant molecular hotspots
characterised by copy number losses and promoter hypermethylation in distinct molecular subtypes of melanoma that
contribute to specific transcriptomic silencing and might indicate a poor clinical outcome of melanoma.
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Introduction
Melanoma is an aggressive, therapy-resistant malignancy of the
melanocytes. The incidence of this disease has been increasing
worldwide, resulting in a growing public health problem [1,2].
Interactions between molecular and environmental risk factors
that promote melanomagenesis are the subject of ongoing research
[3]. There are currently no systemic therapies available to
significantly extend the life expectancy of patients with advanced
melanoma. Therefore, early diagnosis and conventional treat-
ments remain the key to improved survival for all affected
individuals [1,4,5]. Recently, several high-throughput genomic
and gene expression studies have been designed to reveal the
molecular mechanisms involved in melanoma progression [6–14].
DNA microarray technology, a high-throughput screening
methodology, offers an opportunity to simultaneously analyse
the gene expression levels of thousands of genes in the cancer
genome. This technology has been extensively used in cancer
research to identify tumour subclasses, predict disease outcomes
and identify genes associated with drug resistance [15,16].
Previous transcriptome analyses have provided valuable informa-
tion for the assessment of patient group classifications, such as
subgroups of patients who are likely to respond to a particular
therapy [17].
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Many research groups have used different gene expression
platforms to obtain a better understanding of the stepwise
tumourigenesis involved in melanoma development. These studies
have identified cohorts of genes that facilitate distinction of benign
nevi from malignant melanomas [18,19], sub-classification of
metastatic melanomas into distinct subgroups [6,19–23] and
prediction of distant metastasis-free survival [20,24]. Most of
these research groups have found at least two naturally occurring
subgroups using unsupervised clustering. Some researchers have
been unable to find any association between subgroups with any
clinical variables [19,21]. However, other groups found that the
clusters differed in terms of how advanced tumour were, defined
by thickness and survival [20], and the transition from the radial
growth phase (RGP) to vertical growth phase (VGP) [6,22,23].
Microarray studies have been limited in utility because of the lack
of concordance from one study to the next. This limitation
suggests that in addition to tumour heterogeneity, inconsistencies
in the experimental design, sample preparation and platforms used
for analysis have contributed to the diversity of data.
It has recently become apparent that melanoma heterogeneity
may be caused by both alterations in gene expression and distinct
genomic changes [25–29]. Taking a global view of the available
malignant genome and transcriptome has proven to be valuable
for understanding the intricate process of neoplastic transforma-
tion and for obtaining profound downstream benefits from these
discoveries. Despite rapid progress in exploring commonly
amplified and deleted regions and epigenetic changes in melano-
ma, integrated analyses have focused only on melanoma cell lines.
Simultaneous studies have been aimed at exploring commonly
affected genes that exhibit copy number changes and altered gene
expression [30–32], but there has been no study conducted on
melanoma tissues [33].
In this study, our aim was to define the gene expression
signature of previously untreated primary melanomas in patients
with a known clinical history using the Affymetrix GeneChip
Human Genome U133 Plus 2.0 expression arrays platform. We
extended these analyses and correlated the transcriptomic data
with copy number alterations defined using the NimbleGen HG18
CGH 4x72K WG Tiling v2.0 array and the CpG methylation of
promoters analysed by the Illumina GoldenGate Methylation
Assay.
Integrated analysis of different types of data that are charac-
teristic of the same tumour might allow us to identify molecular
pathways and genetic aberrations that could influence the
biological and clinical behaviour of melanomas and pinpoint
progression-related genes, facilitating molecular classification of
the disease. These candidate genes could ultimately be utilised as
therapeutic targets for treating human malignant melanoma.
Materials and Methods
Melanoma Samples
Thirty-six primary melanomas were involved in our gene
expression studies and 17 out of the 36 primary melanomas was
analysed by tiling array CGH and DNA methylation assay.
Tumour tissues were obtained from the Department of Derma-
tology, University of Debrecen, Hungary. All human studies were
conducted in accordance with principles outlined in the Declara-
tion of Helsinki and were approved by the Regional and
Institutional Ethics Committee of the University of Debrecen
Medical and Health Science Center and was conducted according
to regulations (Protocol #2836-2008). Written informed consent
was obtained from each patient. The clinicopathological data on
the 36 primary melanomas are summarised in Table 1 according
to the new melanoma TNM staging system [34,35].
High quality total RNA and genomic DNA were isolated from
fresh tissues. Detailed protocols for routine procedures and quality
controls are available under the Text S1.
Microarray Based Experiments
Gene expression analysis. Gene expression analysis was
carried out using Affymetrix GeneChip Human Genome U133
Plus 2.0 expression arrays The microarray data was published in
the Array Express Archive repository (a MIAME compliant
database) with accession number E-MTAB-946.
Analyses of gene expression data were performed using
GeneSpring 7.3 (Agilent Technologies, Santa Clara, CA, USA)
and BRB Array Tools 4.3.0 developed by Dr. Richard Simon and
BRB Array Tools Development Team. The raw intensity values
from each chip were normalised to the 50th percentile of the
measurements to reduce chip-wide variations in intensity. Each
gene was normalised to the average level of that particular gene to
allow comparison of relative changes in gene expression levels
between different conditions. Only genes showing detection flag
Table 1. Clinical and histopathological parameters of primary
melanomas (N= 36).
Variables No. of primary melanomas
Tumor typea
NM 15
SSM 19
In situ 2
Gender
Male 16
Female 20
Age (years)
20–50 2516613127
.50 29
Breslow thickness (mm)b
,2.00 18
2.01–4.00 6
.4.01 12
Clark’s level
I, II, III 20
IV, V 16
Ulceration
Absent 18
Present 18
Localisation
Trunk 12
Extremities 22
Head 3
Metastasis formationc
Non-metastatic 29
Metastatic 7
aNM: nodular melanoma, SSM: superficial spreading melanoma.
bThickness categories based on the current melanoma staging system.
cMetastases within 5 years after the removal of the primary tumour.
doi:10.1371/journal.pone.0054958.t001
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present in at least 50% of the samples were used in further analyses
(25,886 probe sets).
The log2 transformed data of all samples were classified
according to their expression pattern via hierarchical clustering
using average linkage and Pearson’s correlation. The genes, that
expressed differently among the predefined melanoma groups
(Table 1) at the 2- fold change and p#0.001 level after Benjamini
and Hochberg multiple testing correction, were assessed by
univariate t-test for each gene and were visualized by Volcano
plots. Principal component analysis (PCA) of differentially
expressed genes was applied to verify the proportion and the
significance of the first 3 components covering the total variation.
Kaplan-Meier survival curves and Cox proportional univariate
test were performed to whether the gene expression of a particular
gene significantly influences survival at the p,0.001 level. To
control for patients’ age, gender and clinical covariates on survival
and to predict a survival prediction we used the Penalized Cox
Regression model.
Copy Number Analysis by Array CGH
An array CGH (NimbleGen HG18 CGH 4x72K WG Tiling
v2.0) and the calculation of ratio values were performed on
genomic DNA samples by Roche NimbleGen (Reykjavik, Iceland).
All of the aCGH data was published in the Array Express Archive
repository (a MIAME compliant database) with accession number
E-MTAB-947.
Statistical analyses were conducted with Nexus Copy Number
5.1. For segmentation, we applied the FASST2 algorithm. To
adjust the sensitivity of the segmentation algorithm, we determined
a significance threshold of 1.0E-6 and specified 1000 kb as the
maximum spacing between adjacent probes. The minimum
number of probes per segment was 5 to eliminate small CNAs.
To detect gains and losses, we set the thresholds as 60.3 for gains
and losses.
Significantly different copy number events between ulcerated
versus non-ulcerated melanomas were identified by applying
Fisher’s exact test, and FDR adjustment for correcting multiple
testing was calculated using the Nexus Copy Number 5.1
Comparison feature.
Investigation of the Promoter Methylation Patterns
The quantitative methylation status of the 1505 CpG sites
corresponding to 807 cancer-related gene promoters correspond-
ing to 14 primary melanomas was performed with the Illumina
GoldenGate DNA Methylation arrays as described previously
[36]. Briefly, genomic DNA from tumour tissues was prepared by
overnight proteinase K treatment, phenol-chloroform extraction,
and ethanol precipitation. Sodium bisulfite modification was
performed on 500 ng DNA using the EZ DNA Methylation-Gold
Kit (Zymo Research). BeadStudio v3.2 software (Illumina) was
used for initial filtering and clustering analysis as described
previously [36]. We identified 45 overlapping genes represented by
98 different CpGs between our downregulated gene list (987
genes) and the Illumina Assay. To estimate if the 98 overlapping
CpG sites are methylated differently, we performed univariate t-
tests for each gene by BRB Array Tools. Statistically significant
difference was considered when the P value was less than 0.05
below the 0.1 Benjamini and Hochberg FDR.
Integration of Gene Expression, Copy Number Variation
and Promoter Methylation Datasets
To study the relationship between DNA copy number gains/
losses and mRNA levels, we exported the median of the replicate
probe log2 ratios and the expression values corresponding to the
same genomic region for determining Pearson’s correlation. The
genelist generated through this analysis was imported to the Nexus
5.1 package. We assessed the genomic locations that exhibited
significant copy number losses and concentrations of down-
regulated genes simultaneously. The statistics-generated P value
was based on the number of deregulated transcripts located in
significantly deleted genomic regions after multiple testing
correction.
To verify the effects of cis- regulatory copy number elements on
gene expression and to assess trans- acting copy number
alterations, we used the ‘lol’ R package applying cross-validation
as optimizer [37–39]. Detailed description of this approach is
available under the Text S2.
To assess relation between gene expression and promoter
methylation patterns, we applied Pearson’s correlation for each of
the 98 CpG sites corresponding to the 45 overlapping genes
between the datasets.
Pathway Analysis of the Gene Expression Data
Functional characterisation of differentially expressed genes
(p,0.05) that showed differences of greater than 2-fold between
the melanoma groups (ulcerated melanomas versus melanomas
without an ulcerated surface) was performed using Ingenuity
Pathways Analysis software (IPA, Ingenuity Systems: www.
ingenuity.com) and the Database for Annotation Visualisation
and Integrated Discovery (DAVID, http://david.abcc.ncifcrf.gov)
Gene Functional Classification Tool. Datasets containing gene
identifiers (Affymetrix ID) and the corresponding expression values
were evaluated. Each gene identifier was mapped to its
corresponding gene object in the Ingenuity Pathways Knowledge
Base (IPKB). Functional analysis of the genes was based on the
collection of data summarised and stored in the IPKB database.
Genes identified using the IPA program were categorised
according to location, cellular components and their reported
biochemical, biological, and molecular functions.
Validation of the Gene Expression Microarray Results by
QPCR
The expression status of selected genes was performed using
quantitative real-time PCR in all melanoma samples with the ABI
PrismH 7900HT Sequence Detection System (Applied Biosystems,
Carlsbad, California, USA). Reverse transcription (RT) was
carried out on total RNA (600 ng) using the High Capacity
cDNA Archive Kit, according to the protocol of the supplier
(Applied Biosystems, Carlsbad, California, USA). A TaqMan Low
Density Array with pre-designed TaqManH Gene Expression
Assays (Applied Biosystems, Carlsbad, California, USA) was used
to perform qPCR for 17 genes (Table S1).
Selection of genes covered several genes from Table 2.
according to the following IPA functions: Hair and Skin De-
velopment and Function, Organ Development, Dermatological
Diseases and Conditions (ITGB4, SDC1, FGFR2, FGFR3);
Cancer, Cellular Movement, Cellular Growth and Proliferation
(KLF4, ARHGEF, EGFR); Cellular Development, Hematological
System Development and Function, Hair and Skin Development
and Function (KLK11, KLK5, JUP, EHF); Cancer, Cell Cycle,
Reproductive System Disease (PERP). Additionally, 5 genes
(CTSL, EPSL8L1, EPSL8L2, IL18, RAB25) were randomly
selected from Table S1 comprising 987 genes that had been
proved to be downregulated in ulcerated melanomas by micro-
array technique.
The house keeping genes b-actin (Hs99999903_m1) and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH;
Integrative Genomics of Melanoma Ulceration
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Hs99999905_m1) were used as controls for accurate normalisation
of the gene expression data [40]. Pearson’s correlation was used to
evaluate the strengths of the relationships between the PCR and
the microarray expression data. The Student’s t-test was
performed to validate statistically significant differences among
the predefined sample groups, and the data were considered
significant at p,0.05.
Results
Gene Expression Alterations of Primary Melanomas
Affymetrix oligonucleotide microarrays were used to investigate
the gene expression patterns in 36 primary melanomas. The
follow-up period of the patients was 5 years. The clinicopatho-
logical parameters of the samples are summarised in Table 1.
After the normalisation and quality control steps were
performed for the microarray data, 25,886 probe sets were used
in further analyses. Univariate t- tests were performed on log-
transformed expression values of the probes to determine
differentially expressed genes (P value cut off 0.001, greater than
2-fold change), among all the predefined clinical groups (Table 1).
The analysis resulted in 1,080 genes that expressed differentially
between ulcerated and non-ulcerated melanomas with FDR false
discovery rate of less than 5%. Our results are visualized by
Volcano plot (Figure 1 A). The majority of the differentially
expressed genes were downregulated (987 genes, Table S1),
whereas only 93 genes (Table S2) were significantly upregulated in
ulcerated specimens compared to non-ulcerated melanomas.
Alternatively, hierarchical clustering of the 1,080 differentially
expressed genes distinguished also the primary melanoma
subgroups, and melanomas with a tumour surface ulceration were
clustered mainly together (Figure 1B). To measure how ulcerated
and non-ulcerated groups can be distinguished according to the
1080 differentially expressed genes, we performed Principal
Component Analysis (PCA). Based on the global test of clustering
(p,0.001), the first 3 components covered the 59% of the total
variance.
Using univariate t-tests and PCA for further verification we
were unable to describe differentially expressed genes among other
sample groups categorized by histologycal subtype, Breslow
thickness, Clark level and metastasis formation.
For survival analysis we established Penalized Cox Regression
model that revealed no relationship between patients’ survival and
gene regulation when we considered patients’ age, gender and
other clinical cofounders, including survival.
Functional Categorisation of Differentially Expressed
Genes
The functional annotation of upregulated genes was performed
using the web-accessible programs of the Database for Annotation
Visualisation and Integrated Discovery (DAVID). Of the 93
overexpressed genes, 79 could be identified by DAVID, and 23 of
these genes belonged to the well-known KEGG pathways (Kyoto
Encyclopaedia of Genes and Genomes). These data are sum-
marised in Table 3. The overexpressed genes in the ulcerated
melanoma cluster included many genes with reported functional
roles in cell cycle regulation and proliferation, such as cell division
cycle 25a (CDC25a) and MAPKK12. Out of the 93 genes, the
Table 2. Networks and pathways of downregulated genes associated with ulcerated melanoma surface.
Gene symbol Main function (IPA)a Signaling pathways (KEGG)b
ANK3, CLCA2, DSC1, DSG1, DSG3, DSP, DST, EVPL,
FGFR2, FGFR3, FLG, IRF6, ITGB4, IVL, JUP, KLK7,
KRT5, KRT10, MAPK13, NTRK2, PKP1, POU2F3,
PPL, S100A7, SDC1, SERPINB5, SFN, SULF1, TP73L
Hair and Skin Development and Function,
Organ Development, Dermatological
Diseases and Conditions
Olfactory transduction: CLCA2; Cell Communication: DSC1, DSG,
DSG3, ITGB4, KRT5, KRT10; MAPK signaling pathway: FGFR2,
FGFR3, MAPK13; Cell adhesion molecules: SDC1
ALDH2, ARHGEF4, ASS1, AURKA, BCL11B, CA2,
EGFR, ETS2, GATA3, GJA1, KLF4, KLF5, LAMA3,
LGALS7, MAF, PTGS1, SCNN1A, SERPINB3,
SLC2A1, SPP1, THBD, TPSAB1, WNT5A
Cancer, Cellular Movement, Cellular Growth
and Proliferation
Metabolism: ALDH2, ASS1, CA2, PTGS1; Regulation of
cytoskeleton: ARHGEF4; Cell cycle: AURKA; Adherens junction:
EGFR; Axon guidance : ETS2; Cell Communication : GJA1, LAMA3,
SPP1; Hemostasis: THBD; Wnt Signaling pathway: WNT5A
AHNAK, ANKRD57, CA12, CD24, CXADR, DEFB1,
EPHB6, EPPK1, EVA1, FGFR2, FZD10, GABRE,
GJB3, GRHL2, PRSS, SDC1, SERPINB5, SPINK5
Cancer, Tumor Morphology, Cellular
Movement
Metabolism : CA12; Hematopoietic cell lineage: CD207; Axon
guidance: EPHB6; MAPK signaling pathway: FGFR2; Wnt signaling
pathway: FZD10; Neuroactive ligand-receptor interaction: GABRE,
PRSS3; Cell Communication: GJB3; Cell adhesion: SDC1
BICD2, C20ORF42, CD207, CDKN1C, COL4A6,
COL7A1, CST6, CSTA, FCER1A, KLK11, KRT1,
LAD1, LY6D, PDZK1IP1, SPINT2, SPRR1A, ST14
Cancer, Cellular Growth and Proliferation,
Hair and Skin Development
and Function
Cell Communication: COLA7A1, KRT1
ABLIM1, AKR1B10, CENTD1, CXCL14, DSC3, EFS,
F2RL1, FGF2, GJA1, IMPA2, KLK8, KRT15, LTB4R,
MAP7, RORA, VSNL1
Cell-To-Cell Signaling and Interaction,
Cellular Growth and Proliferation,
Cancer
Axon guidance: ABLIM1; Metabolism: AKR1B10, IMPA2; Cytokine-
cytokine receptor interaction : CXCL14; Cell Communication:
DSC3, GJA1, LFRT15; MAPK signaling pathway: FGFR2;
Neuroactive ligand-receptor interaction: F2RL1, LTB4R
AKR1C1, AKR1C2, AQP3, BCL11A, CKMT1B,
CTNNBIP1, EHF, GNA15, IGF1, JUP, LOR, NMU,
PKP3, SCEL, SPRR1B, TACSTD2
Cellular Development, Hematological
System Development and Function, Hair
and Skin Development and Function
Metabolism: AKR1C1, AKR1C2, CTKMT1B; Wnt signaling
pathway: CTNNBIP1; Calcium signaling pathway: GNA15
AIM1, CLTB, CPA3, DGKA, FAT2, KRT15, LYPD3,
MYO6, PAK6, PERP, PTGS1,TUBB4
Cancer, Cell Cycle, Reproductive
System Disease
Huntington’s disease: CLTB; Cell Communication: KRT15;
Metabolism: DGKA, PTGS1; Focal adhesion: PAK6; Gap junction:
TUBB4
CALML3, CALML5, CCRL1, PRSS8, SDC1, SPP1,
THBD
Cellular Movement, Cell-To-Cell Signaling
and Interaction, Hematological System
Development and Function
Calcium signaling pathway: CALML3; Cell adhesion molecules:
SDC1; Cell Communication: SPP1; Hemostasis: THBD
aIPA: Ingenuity Pathways Analysis;
bKEGG Kyoto Encyclopedia of Genes and Genomes.
doi:10.1371/journal.pone.0054958.t002
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expression of the osteopontin (SPP1) gene showed the greatest
difference between the two melanoma subgroups (fold change
value: 6). Most of the genes from the KEGG pathways were linked
to cell adhesion/extracellular matrix (ECM) interactions. These
genes include osteopontin, beta-catenin, syndecan 3, Shc family
member 4 and v-akt murine thymoma viral oncogene homolog 3,
which affects the MAPK and ErbB signalling pathways. Two
additional genes (CCR1 and EPOR) were involved in cytokine-
cytokine receptor interactions. Increased expression was also
detected of genes in different (e.g., pentose, fructose, inositol)
metabolism pathways.
Detailed analysis using Ingenuity Pathway Analysis, GeneGo
software and the DAVID program revealed networks, pathways
and interactions that were enriched for genes that were down-
regulated in melanomas with an ulcerated surface (987 genes).
According to the functional role of the genes, 26 networks were
identified via IPA analysis. These networks are related to hair and
skin development and functions, dermatological diseases and
conditions, cellular development, cellular growth and prolifera-
tion, cardiovascular system development and function, cell
morphology, cellular assembly and organisation, and cell-to-cell
signalling and interactions (Table 2). For example, the ‘‘Cancer,
Cellular Movement, Cellular Growth and Proliferation’’ network
encompasses EGFR, FGFR2 and other key genes, such as
AURKA, a cell cycle checkpoint mediator, and SPP1, LAMA3
and GJA1, which play a role in cell communication.
In the analysed melanomas, the ‘‘Cell adhesion, Cadherin’’
network was significantly enriched for genes for which decreased
expression is correlated with ulceration (p,0.0001). This network
involves genes playing a significant role in the Wnt (WNT16,
Figure 1. Gene expression patterns of primary melanomas. A: The Volcano plot displays the relationship between fold changes and statistical
significance: the x-axis visualizes the log2 values of the fold change while the y-axis belongs to the log10 values of significance. The green line of the x-
and y-axes indicate greater than 2-fold change between ulcerated and non-ulcerated samples and P value cut off 0.001 revealed by univariate t-tests
for each gene. The Benjamini and Hochberg false discovery rate was applied as multiple test correction. B: Unsupervised hierarchical clustering of the
1080 genes which expressed differentially among ulcerated and non ulcerated melanomas. Samples are displayed vertically and genes are displayed
horizontally. Annotation track marks ulcerated samples with violet and non-ulcerated with green colour. The colour in each cell of the table
represents the median-adjusted expression value of each gene. Yellow indicates increased expression relative to the median, while blue represents
decreased expression. C: Principal Component Analysis for distinction of ulcerated (green dots) and non-ulcerated (blue dots) samples based on the
1080 differentially expressed genes. The analysis revealed that according to the first 3 components which covered the 59% of the total variance the 2
groups were significantly different (p,0.001).
doi:10.1371/journal.pone.0054958.g001
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WNT3, WNT4, WNT5a), beta-catenin, EGFR, FZD10 and p21
signalling pathways (Figure S1). Interestingly, the members of the
Wnt family that have been reported to be overexpressed in the
majority of melanomas were overexpressed only in one subset of
our melanoma samples. This analysis also revealed that the
expression levels of distinct components of the ‘‘Junctional
Mechanism Regulation Pathway’’ (i.e., ZO-2, OCLN, GJA1,
CLDN1, DSP, JUP) were differentially expressed in the analysed
tumours (Figure S2) ZO-2 (TJP2) is a tight junction plaque adapter
for the recruitment of cytosolic molecules implicated as integral
membrane proteins involved in cell signalling, and Occludin
(OCLN) and Claudin 1 (CLNDN1) serve as linkers of the actin
cytoskeleton to the plasma membrane and contribute to cytoskel-
eton organisation, small GTPase-mediated signal transduction,
and cellular component organisation. Downregulation of laminin
5, collagen IV and ezrin is related to integrin-mediated cell-matrix
adhesion, playing a key role in cell surface structure adhesion,
migration and organisation. Compared to melanomas without
ulceration, ulcerated melanomas were characterised by down-
regulation of members of the kallikrein serine protease family (i.e.,
KLK7, KLK5, KLK11), which are related to angiogenesis and the
degradation of extracellular matrix components. The top five
identified networks that were affected in tumours with ulcerated
surfaces were centred on key genes involved in the p53, Nf-
kappaB, WNT/beta-catenin pathways.
Validation of Expression Microarray Results via
Quantitative RT-PCR
The microarray results were validated by performing qRT-PCR
measurements of the 17 downregulated genes. Each of the 36
tumour samples included in the microarray analysis was tested
using a qPCR based TaqMan Low Density Array.
For all of the 17 genes, the expression levels differed between
melanomas with or without ulceration (more than a 2-fold change,
p,0.05). These data showed a strong correlation with the
microarray results. Six of the genes displayed a highly significant
(p,0.01) expression difference between the melanoma groups
(Figure 2). Two of the genes (KLK11 and KLK5) belong to the
protein-degrading kallikrein family. The KLF4 transcription factor
showed decreased expression (by PCR as well) and is capable of
both activating and repressing genes involved in cell-cycle
regulation and differentiation. Furthermore, fibroblast growth
factor receptor 2 (FGFR2); ARHGEF4, which acts as a guanine
nucleotide exchange factor; and SDC1, a member of the syndecan
Table 3. Functional annotation of the upregulated genes in ulcerated melanomas.
Affymetrix ID Gene Name KEGG Pathwaya
209875_s_at secreted phosphoprotein 1 (osteopontin) Cell Communication, Focal adhesion, ECM-receptor interaction,
Toll-like receptor signaling pathway
223679_at catenin (cadherin-associated protein), beta Wnt signaling pathway, Focal adhesion, Adherens junction,
Tight junction
202898_at syndecan 3 (n-syndecan) ECM-receptor interaction, Cell adhesion molecules (CAMs)
242879_x_at v-akt murine thymoma viral oncogene homolog 3 MAPK signaling pathway, ErbB signaling pathway, mTOR
signaling pathway, Apoptosis, VEGF signaling pathway, Focal
adhesion, Tight junction, Toll-like receptor signaling pathway,
Jak-STAT signaling pathway
235238_at, 230538_at shc (src homology 2 domain containing) family, member 4 ErbB signaling pathway, Focal adhesion
205099_s_at chemokine (c-c motif) receptor 1 Cytokine-cytokine receptor interaction
215054_at erythropoietin receptor Cytokine-cytokine receptor interaction, Jak-STAT signaling
pathway
204015_s_at dual specificity phosphatase 4 MAPK signaling pathway
205447_s_at mitogen-activated protein kinase kinase kinase 12 MAPK signaling pathway
1555772_a_at cell division cycle 25a Cell cycle
209435_s_at rho/rac guanine nucleotide exchange factor (gef) 2 Cell cycle
203651_at, 240859_at, 1554638_at zinc finger, fyve domain containing 16 TGF-beta signaling pathway
221489_s_at sprouty homolog 4 Jak-STAT signaling pathway
224341_x_at toll-like receptor 4 Toll-like receptor signaling pathway
206617_s_at renin binding protein Aminosugars metabolism
204271_s_at endothelin receptor type b Calcium signaling pathway, Melanogenesis
205119_s_at formyl peptide receptor 1 Neuroactive ligand-receptor interaction
212884_x_at apolipoprotein e Neurodegenerative Diseases
201660_at,
201661_s_at
acyl-coa synthetase long-chain family member 3 PPAR signaling pathway
204044_at quinolinate phosphoribosyltransferase Nicotinate and nicotinamide metabolism
201272_at aldo-keto reductase family 1, member B1 Pentose and glucuronate interconversions, Fructose and
mannose metabolism, Galactose metabolism
222240_s_at myo-inositol 1-phosphate synthase a1 Inositol phosphate metabolism
203217_s_at st3 beta-galactoside alpha-2,3-sialyltransferase 5 Glycosphingolipid biosynthesis
aKEGG: Kyoto Encyclopedia of Genes and Genomes.
doi:10.1371/journal.pone.0054958.t003
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proteoglycan family, were also expressed at significantly lower
levels in ulcerated tumours. These genes are part of the ‘‘Cancer,
Cellular movement, Cellular Growth and Proliferation’’ network
and the ‘‘Hair and Skin Development and Function’’ network.
Comparison of Gene Expression Changes to Copy
Number Alterations and DNA Methylation Patterns in
Primary Melanomas
We performed a detailed aCGH analysis on 17 melanomas and
collected integrated array CGH and gene expression data from the
same tumour to characterise genetic alterations that might be
associated with gene expression changes.
A genome-wide aCGH profiling analysis revealed numerous
copy number alterations in the melanoma genome. Ulcerated
melanomas displayed gains at 3p, 6p, 7p, 7q, 8q, 11p, 11q, 15q,
16p, 17q, 18q and 22q, with the smallest regions detected at
3p21.31-p21.2, 6p21.2-p21.1, 7p14.3, 7q36.2, 8q24.3, 11p15.5-
p15.4, 11q13.3, 15q22.33-q23, 15q24.2, 16p13.3, 17q25.3,
18q21.1 and 22q12.3. Losses were found at 4q, 7q, 9q, 11p,
14q, 15p, 15q, 17q, 20q, 21p with the smallest regions observed at
4q28.3, 7q11.1, 9q12, 9q13, 11p11.2-p11.12, 14q11.1-q11.2,
15p11.1- q11.1, 17q21.31, 20q11.1, 21p11.2 (p,0.05). Table 4
summarises the most frequent and statistically significant copy
number losses associated with melanoma ulceration.
To determine the influence of copy number aberrations on the
gene expression changes in primary melanomas, we sought to
identify the genes whose expression was significantly correlated
with copy number changes. By correlating the intensity of the
aCGH ratios (median log2) with the expression levels of previously
identified downregulated genes (987 genes), we identified 150
genes whose expression was significantly and positively correlated
with copy number changes in ulcerated melanomas (p,0.05,
Table S3). The gene list generated through this analysis was
significantly enriched in genes mapping to chromosomes 6q and
10q (Table 5). Figure 3 shows the frequency distribution of copy
number losses in ulcerated (red line) and non-ulcerated (green line)
melanomas. We found more narrow regions that were deleted on
the long arm of chromosome 6 (6q14.1-q14.2, 6q16.3-q21,
6q22.31-q22.32, 6q23.3 and 6q24.2), consisting of 9 deregulated
genes (ELOV4, ME1, TPBG, AIM1, TPD52L1, IL20RA,
HEPB2, PERP and UTRN). A significant association between
genomic losses and the downregulation of genes on chromosome
10 was only observed for one gene (ABLIM1, localised to 10q25).
Lasso regression, performed by lol R-package, identified both
copy number gains (Figure 4 B) and losses (Figure 4 A) as top
Figure 2. Quantitative RT-PCR validation of the 17 selected genes from the list of 987 downregulated transcripts. The boxplots
represent mRNA expressions of ulcerated (in red colour) versus non-ulcerated (in blue colour) primary melanomas. Gene expression differences
among the groups were analysed using the Student’s t-tests (**p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0054958.g002
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scoring (Scoretrans $0.5) trans- acting somatic DNA aberrations
accompanied by transcriptomic alterations. Interestingly, even
trans- acting copy number gains were accompanied by transcrip-
tomic silencing, there was no association between gains and gene
upregulation revealed. Three distinct copy number losses (9p21.3,
9q21.11 and 7q11.23) were related to the downregulation of
Anoctamin1 (Ano1), whereas Ezrin (EZR) deregulation was
probably caused by the copy number loss of 6q27 (Figure 4 A)
Table 4. Distribution of the most frequent and statistically significant copy number losses in ulcerated surfaced melanomas.
Cytoband Location Region Length (bp) Frequencya (%) P valueb
Distribution of known CNV
overlapc (%)
4q28.3 470255 29 0.020 27
7q11.1 468074 29 ,0.001 94
9q12 179861 53 0.005 0
9q13 379778 53 0.005 72
11p11.2-p11.12 945190 35 ,0.001 5
15p11.1-q11.1 682823 29 ,0.001 0
15q11.1 463101 29 ,0.001 41
17q21.31 160872 29 0.007 0
20q11.1 691516 35 ,0.001 0
20p11.2 319491 76 ,0.001 0
aCopy number loss frequency indicates the proportion of samples that exhibit the given genomic loss.
bP value has been determined by a multiple corrected Fisher’s exact test.
cCNV overlap is the occurrence of copy number events that exist in healthy donors according to the Copy Number Project database (Wellcome Trust Sanger Institute).
doi:10.1371/journal.pone.0054958.t004
Figure 3. Correlation of copy number alterations (CNAs) and gene expression. Chromosomes 6 and 10 shows significantly different copy
number losses that are highly correlated with gene downregulation based on comparison of CNAs in the ulcerated vs. non-ulcerated tumour
subgroups. The differences in CNAs (red indicates CNA losses, and green indicates CNA gains) were obtained by subtracting the alterations in the
ulcerated group (above the baseline) from the alterations in the non-ulcerated group (below the baseline) using Fisher’s exact test corrected for
multiple testing. A multiple corrected t-test was performed to determine the number of downregulated genes located in significantly deleted
genomic regions. Five narrowed deleted regions were found on chromosome 6 and one deleted region was detected on chromosome 10q that was
also downregulated.
doi:10.1371/journal.pone.0054958.g003
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and the copy number gain of 17q22 (Figure 4 B).Cis- affecting
copy number losses given in Table 5 were verified by Lasso-
regression as we revealed Scorecis values more than 0.5 for each
region.
To define the influence of the epigenetic alterations on
melanoma ulceration, we estimated if the 98 overlapping CpG
sites were methylated differently by univariate t- tests for each
genes. Figure 5A plots a clustered heat map showing the lack of
differences between the sample groups with an exception of JAK2
and IL1RN genes (Figure 5B), however, significant differences did
not remained after adjustment of multiple comparison (Figure 5C).
Furthermore, we correlated the gene expression data with the
observed epigenetic changes (Illumina Golden Gate Cancer Panel
1) in the same tumour. Of the 987 downregulated genes identified
using the Affymetrix microarray, we found 45 common genes
represented by 98 different CpGs on the methylation array
platform. A strong or medium inverse correlation (a medium
inverse correlation was assessed if r#20.30 and a strong inverse
correlation if r#20.50 by Pearson’s correlation) between gene
expression and methylation levels was detected in the case of 11
genes corresponding to 17 different CpG sites. Detailed list of
these genes are shown in Table 6.
Discussion
Malignant melanoma develops from the malignant transforma-
tion of melanocytes, the pigment-producing cells in the basal
epidermal layer of human skin, and is one of the most aggressive
human cancers. Melanoma arises from the accumulation of
different alterations in genes that are critical for cell proliferation,
differentiation, and cell death [41,42]. To develop treatments for
advanced melanoma and to increase survival in metastatic
melanoma patients, it is important to characterise the genetic
and gene expression changes leading to each progressive step of
the disease.
During the last decade, microarrays have become the technol-
ogy of choice for the selection of the genes responsible for the
behaviour of malignant lesions. Previously published microarray
results have shown highly different and frequently contradictory
‘‘melanoma signatures’’ containing many genes whose functional
roles in melanoma progression have not been well characterised.
Furthermore, the gene sets found in different microarray studies
overlap poorly with each other [20,21,43,44]. In this study, we
defined the gene expression profiles in 36 primary melanoma
tissues and correlated these data with DNA copy number
alterations and epigenetic changes in the selected samples. Using
the Affymetrix microarray platform, we identified 1,080 genes
with expression value that was significantly associated with the
tumour surface ulceration of the primary tumours. The American
Joint Committee on Cancer has recently reported that after
Breslow thickness, the presence or absence of ulceration is the
second most powerful independent predictor of survival for
melanoma patients [35,45]. While the molecular background of
melanoma ulceration is still unclear, according to the most recent
study involved 4,661 patients, not only the presence but the extent
of ulceration could be independent predictors of survival [46].
Furthermore, ulceration was reported to be significant predictive
factor for outcome of adjuvant interferon treatment [47]. All of
these results prompt further efforts in designing additional studies
to obtain better insights into the molecular level of ulceration.
Our functional analysis revealed that the majority of the
differentially expressed genes were downregulated (987 genes) and
were involved in the p53, Nf-kappaB, and WNT/beta-catenin
pathways. In agreement with previous studies, we also observed
downregulation of pro-apoptotic genes (e.g., TPL73L and
P53AIP1), members of the forkhead box gene family (e.g.,
FOXQ1) and members of the TNFRSF25 and TNFSF10 protein
families [7].
According to the literature, osteopontin expression is closely
associated with shortened relapse-free survival and other histolog-
ical variables, including ulceration, that predict relapse and are
associated with metastatic dissemination [48–50]. In this study, we
have demonstrated that osteopontin is significantly overexpressed
in ulcerated melanomas. Our finding agrees with previous studies
and supports the assumption that osteopontin expression is
a potential biomarker of melanoma progression [48,50].
For obtaining a better insights into the molecular mechanisms
that might be responsible for the aggressive phenotype associated
Table 5. Genomic regions enriched with downregulated genes affected by significant genomic losses in ulcerated melanomas.
Cytoband Location
Region Length
(bp)
CNV Loss Frequency
in Ulcerated
Samplesa (%)
CNV Loss Frequency
in Non-ulcerated
Samplesb (%) P valuec
Known CNV
Overlapd (%) Downregulated Genes
6q14 2239920 47 0 0.023 0 ELOVL4
ME1
TPBG
6q21 2010714 53 0 0.009 2 AIM1
6q22.31-q22.32 2121683 53 0 0.009 2 TPD52L1
6q23.3 1160478 53 0 0.009 0 IL20RA
HEPB2
PERP
6q24.2 118530 47 0 0.023 0 UTRN
10q25.3 368863 47 0 0.023 8 ABLIM1
aCopy number loss frequency in ulcerated samples indicates the proportion of ulcerated melanomas exhibiting the particular genomic loss.
bCopy number loss frequency in non-ulcerated samples indicates the proportion of melanomas exhibiting the particular genomic loss.
cP value has been determined by a multiple corrected t-test considering the numbers of downregulated transcripts located on significantly deleted genomic regions.
dKnown CNV overlap is the occurrence of copy number events existing in healthy donors according to the Copy Number Project database (Wellcome Trust Sanger
Institute).
doi:10.1371/journal.pone.0054958.t005
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with the observed gene expression signatures of ulcerated
melanomas, we extended our study to search for DNA copy
number alterations and epigenetic changes that might influence
transcription. Array CGH is currently the best tool for searching
for non-random DNA copy number alterations in cancer genomes
and finding new genes that harbour copy number gains or losses
with prognostic relevance [51–53]. As a result of improved
resolution, there is currently an abundance of CGH data available
in both large genomic regions and for uniquely affected genes.
However, these studies focused little on elucidating the genomic
Figure 4. Trans-acting copy number alterations. Lasso regression was performed on the previously identified 1080 differentially expressed
genes to assess trans- acting copy number alterations on mRNA expression. Cytoband locations were mapped by UCSC Genome Browser and the
tables below represent the genes whose expression can possibly be affected by CN losses (A) and gains (B) at trans-acting CN elements. The
scoretrans represents the strength of the relationship between trans-acting elements and mRNA expression.
doi:10.1371/journal.pone.0054958.g004
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alterations that contribute to gene regulation. Valseria et al. were
the first to highlight SCNA (somatic copy number alteration)
genes. The downregulation and upregulation of these genes is
accompanied by genomic losses or gains in melanoma [9]. The
present study revealed new genes that might give better insight
into copy number alteration (CNA)-induced gene regulation.
Because the experiments were based on a metastatic cell line, the
aforementioned authors failed to find any progression-related
clinical effects associated with these SNCA genes.
The main purpose of this part of the study was to give functional
relevance to the copy number events by providing a statistically
powerful integrated interpretation of gene expression changes and
copy number alterations. Based on our aCGH analyses, we found
more regions on chromosome 6q and only one region on
chromosome 10q that showed significantly different loss of copy
numbers between the two clinical subgroups. It is important to
note that these regions were enriched for the downregulated
transcripts and significantly correlated with our previously defined
gene expression results. There are a total of 36 genes in these two
regions, among which we identified 10 downregulated transcripts
using the Affymetrix microarray. It is important to note that these
genes include TPBG, PERP and UTRN, which are involved in
cell-cell and cell-matrix adhesion. PERP also functions as a p53-
induced apoptosis effector molecule. Furthermore, TPD52L1
participates in apoptosis followed by nuclear fragmentation.
According to the literature, IL20RA is a tissue-specific Interleukin
Receptor that is highly expressed in normal skin [54]. The
remaining 5 genes could not be directly associated with
carcinogenesis; however, a detailed, functional analysis is needed
to precisely define the role of each of the new genes we have
identified. It is worth noting that previous high-resolution aCGH
experiments have also provided convincing evidence of the
importance of copy number alterations at 6q, as this region often
experiences hemizygous deletion, with MYB1 being the only gene
specified on 6q23 [53,55]. These experiments also suggest that
copy number alterations in MYB1 are an important discriminator
between melanomas and nevi, as validated by FISH in 123
melanomas and 110 nevi. This study supports the assumption that
6q23 can assist in the diagnosis of melanoma. In agreement with
previous findings, we further support the idea that the deletion of
6q23 is an important alteration in melanoma progression.
However, it should also be pointed out that additional new genes
(IL20RA, HEPB2 and PERP) that are located in this region and
are downregulated might make significant contributions to
melanoma progression. In addition to 6q23, we found a significant
association between the tendency towards gene deregulation and
DNA sequence deletions at 6q14, 6q16, 6q22, 6q24 and 6q25.
Somatic copy number alterations at 10q were characterised in
Figure 5. Relationship between DNA methylation and melanoma ulceration. Clustered heatmap, performed to demonstrate promoter
methylation patterns, shows lack of differences between ulcerated and non- ulcerated sample groups. The heatmap is based on the univariate t-tests
performed for each sites (specific for 45 independent genes) that overlapped with the gene expression results. Two genes (IL1RN and JAK2)
demonstrated increased methylation for the ulcerated sample group, however, significant differences did not remain after adjustment for multiple
comparison.
doi:10.1371/journal.pone.0054958.g005
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many cases, but particularly attributed to the PTEN tumour
suppressor gene [56].
While systematic correlation analysis among the copy number
events and the corresponding genes captures cis- effects it is also
important to measure trans- acting copy number alterations (DNA
aberrations on one gene affect the mRNA expressions of other
genes); for the latter purpose we used ’’lol’’ R package developed
by Yuan et al. [39], which provided also an appropriate method
for validating the cis- acting elements.
Regarding the trans- regulatory copy number elements, the top
scoring (Scoretrans) alterations included copy number gains and
losses, however, both types of alterations were associated with
transcriptomic deregulation. The week immunostaning of EZR
protein in the majority of melanomas was mentioned by a single
study, however, this phenomenon was not associated with
ulceration [57]. In our study, we showed that EZR (6q25.3)
deregulation was related to the copy number loss of 6q27 and the
copy number gain of 17q22 suggesting the trans regulatory effects
of these copy number alterations. Frequent loss of 9p21 region is
a well characterized copy number aberration in melanomas
[58,59], however, it has not been mentioned as a trans- regulatory
element for Anoctamin 1 gene (11q13.3) so far. As our results
demonstrated, the transcriptomic regulation of this gene can be
possibly disturbed also by copy number loss of 9q21.11 and
7q11.23 regions.
Parallel to identifying genetic alterations via aCGH, we sought
to examine our external dataset of methylation patterns of 1,505
CpG sites corresponding to 807 selected, cancer-related genes.
Despite the substantial number of candidate genes that have been
shown to be methylated in melanoma, only a few genes were
identified as contributors to disease progression [60]. The major
reason for this might be that most of these studies have been based
on melanoma cell lines and have provided ambiguous results. Few
direct experiments have focused mainly on elucidating the
differences in methylation patterns between melanomas and
benign skin lesions. However, these studies have had a greater
impact regarding understanding what drives melanocytic lesions to
develop into malignant tumours rather than on the progression of
tumours [61].
By correlating 45 overlapping genes between the gene
expression dataset and the methylation assay, we identified 11
genes exhibited inverse relationships. Two (EPHB3, EPHB6) of
the 11 genes are members of the erythropoietin-producing
hepatocyte kinase B (EPHB) receptor family. Both of these genes
play a suggested role in tumour suppression via regulating cell
adhesion and migration. In addition, these genes have downstream
effects on several members of the kallikrein family, which we also
found to be downregulated in ulcerated melanomas in line with
other groups [15]. Based on our data, we assumed that the
downregulation of 2 fibroblast growth factor receptors (FGFR2,
FGFR3) probably resulted from promoter hypermethylation of the
coding genes. In the literature, downregulation of the remaining
genes (CDH13, DST, ETS2, JAG1, ITGA2, PTGS1, TIAM1)
have not been mentioned due to promoter hypermethylation so
far.
Even with no detection of direct relationship of ulceration and
promoter methylation, the above mentioned inverse correlations
support the claim that similarly to copy number variation,
promoter hypermethylation also plays an important role in
transcriptomic silencing. Notably, it was suggested in the literature
that Knudson’s two-hit hypothesis is often achieved through
a combination of DNA methylation and copy number alteration to
the same gene [62,63]. Due to limitation of our studies, parallel
detection of both types of somatic alterations was not achieved in
primary melanomas. Nevertheless, the inverse relation between
gene expression and methylation of the corresponding genes,
together with global presence of copy number alteration should be
taken into consideration, which suggests that somatic aberrations
do not act separately but represent different utility in an integrated
apparatus that acts together and develops transcriptomic silencing
in ulcerated melanomas.
In summary, this study has provided evidence that the gene
expression signatures of primary melanomas are suitable for
distinguishing patients with poor and favourable prognoses. We
have also shown that different patterns of genetic and epigenetic
aberrations associated with distinct molecular subtypes of the
disease contribute to the specific transcriptomic profiles of these
genes. We believe that our systematic correlation of gene
regulation, methylation pattern and the DNA copy number
alteration data in the same cohort of primary melanomas will be
useful for finding new genes and will allow further functional
utilisation of those genes. This study has important implications as
we continue to develop a better understanding of the metastatic
process associated with melanomas, which will allow us to identify
specific genes for use as prognostic markers and, possibly, for
targeted therapeutic approaches.
Supporting Information
Figure S1 Cell adhesion and Cadherin signalling net-
work. The network was significantly enriched of those genes
which decreased expression is correlated with ulceration
(p,0.001). Red circles indicate the downregulated genes.
(TIF)
Table 6. Genomic regions enriched with downregulated
genes affected by promoter hypermethylation.
Gene Symbol
Cytogenetic
Location Probe ID Pearson’s r
EPHB3 3q27.1 EPHB3_E0_F 20.56
EPHB3_P569_R 20.39
FGFR3 4p16.3 FGFR3_E297_R 20.44
FGFR3_P1152_R 20.11
ITGA2 5q11.1 ITGA2_E120_F 20.60
ITGA2_P26_R 20.40
DST 6p12.1 DST_E31_F 20.38
DST_P262_R 20.41
EPHB6 7q34 EPHB6_P827_R 20.34
PTGS1 9q33.3 PTGS1_E80_F 20.45
PTGS1_P2_F 20.25
FGFR2 10q26.13 FGFR2_P266_R 20.37
FGFR2_P460_R 20.29
CDH13 16q23.3 CDH13_E102_F 20.50
CDH13_P88_F 20.37
JAG1 20p12.2 JAG1_P66_F 20.47
TIAM1 21q22.11 TIAM1_P117_F 20.34
TIAM1_P188_R 20.20
ETS2 21q22.2 ETS2_P684_F 20.69
ETS2_P835_F 20.33
doi:10.1371/journal.pone.0054958.t006
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Figure S2 Junctional Mechanism Regulation Pathway,
enriched of those genes which decreased expression is
correlated with ulceration (p,0.001). Red circles indicate
the downregulated genes.
(TIF)
Table S1 Downregulated transcripts (N =987) in ulcer-
ated melanomas.
(DOC)
Table S2 Upregulated genes (N =93) in ulcerated
melanomas.
(DOC)
Table S3 Genes for which expression significantly
positively correlate with copy number changes in
ulcerated melanomas.
(DOC)
Text S1 High quality total RNA and DNA isolation,
quality controls.
(DOCX)
Text S2 Evaluation of cis- and trans acting copy number
alterations.
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